Thromboembolic disease markers
AssigneeGendiag.exe, S.L.
InventorsEduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
Claims5
A method comprising detecting the presence or absence of a combination of single nucleotide polymorphisms (SNPs) in a biological sample isolated from a human subject, wherein the combination of SNPs consists of:
- Serpin A10 (protein Z inhibitor) Arg67Stop (rs2232698), Serpin C1(antithrombin) Ala384Ser (Cambridge II), factor XII C46T (rs1801020), factor XIII Val34Leu (rs5985), Factor II (prothrombin) G20210A (rs1799963), factor V Leiden Arg506Gln (rs6025), factor V Cambridge Arg306Thr, factor V Hong Kong Arg306Gly, ABO blood group rs8176719, ABO blood group rs7853989, ABO blood group rs8176743, and ABO blood group rs8176750 wherein the presence or absence of the polymorphisms is identified by hybridization to specific probes consisting of SEQ ID NO:s:
- 1 to 24 spotted on a microarray.
Dependencies are inferred from the claim text.